Catalent Expands Integrated Softgel Operations Through Coating and Packaging Investment in Eberbach, Germany

Share Article

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it will add new coating and blister packaging equipment at its 360,000 sq ft, Eberbach, Germany softgel manufacturing facility, expanding the integrated softgel solutions available. Coating services are expected to be operational in early 2015, with the packaging equipment expected to be online in the middle of the calendar year.

Catalent's Eberbach, Germany Facility

Providing an integrated service enhances process efficiency and control, and so improves supply lead time, potentially enabling our customers to reduce safety stock and extend product shelf life upon delivery.

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it will add new coating and blister packaging equipment at its 360,000 sq ft, Eberbach, Germany softgel manufacturing facility, expanding the integrated softgel solutions available. Coating services are expected to be operational in early 2015, with the packaging equipment expected to be online in the middle of the calendar year.

The new coating equipment, designed to coat softgels for controlled, enteric and targeted release, will be capable of processing more than 300 million capsules per year and complements Catalent’s existing softgel coating capability at the company’s 78,000 sq ft, Beinheim, France facility. Catalent has conducted extensive studies to demonstrate the advantages of film coating softgels, including their physical stability protection under high storage temperatures and humidity.

"Providing an integrated service enhances process efficiency and control, and so improves supply lead time, potentially enabling our customers to reduce safety stock and extend product shelf life upon delivery,” commented Dr. Richard Lackner, General Manager, Catalent Pharma Solutions, Eberbach.

As the originator of the RP Scherer softgel rotary die process, Catalent continues to innovate with new, breakthrough softgel technologies such as OptiShell™, a plant-derived capsule suitable for complex fill formulations, OptiGel™ Bio for macromolecules, and OptiGel™ Lock designed for abuse deterrence.

About Catalent
Catalent Pharma Solutions is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,000 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and in fiscal 2014 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.™

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Chris Halling

Richard Kerns
Northern Exposure PR
+44 7974 579202
Email >
Visit website